HELPING DRUG DEVELOPERS AND THEIR BACKERS JUDGE MANUFACTURING & AUTOMATION RISKS
Promising Biology. Investable Asset.
The execution liabilities aren’t always visible.
We help you judge whether your manufacturing plan is technically sound and commercially sensible, with regulatory expectations factored in, while you can still change it.
Most manufacturing plans are evaluated in pieces: the process in one place, the economics in another, regulatory expectations later. We look at all of it together, because a change in one shifts the others.
The harder the product is to make e.g. complex modalities and advanced therapies, the more it matters.
THE PROBLEM
The production plan looks fine until it is executed.
Standard biopharma due diligence relies heavily on clinical data and scientific merit. Manufacturing and quality often get looked at too late. Process details, manufacturing readiness, and the case for automation (return on investment included) all need evaluating early. Total cost of ownership and cost per releasable run are where problems usually surface too late.
Chirasoph was built to address that.
We focus on evaluating assets in the pre-Phase II window — where processes aren’t locked in, manufacturing risks can still be assessed and decisions can still be reversed.
64%
Drug launch delays are manufacturing failures.
— Accenture
40%
Clinical halts in CGT are linked to manufacturing and quality.
— BioProcess International
+3.5 years
Median approval delay from scaling and process related failures.
— Chirasoph’s internal analysis
OUR APPROACH
Our analysis runs on tools we are building in-house.
Three tools to assess technical risk (ORYX), cost (IBEX) and strategy (TAHR) while you can still change course.
01
ORYX
Can it be made at scale?
Where the move from bench to manufacturing gets risky.
02
IBEX
What will it cost?
Manufacturing economics and case for automation (or not).
03
TAHR
Will the plan hold up?
Tested against slower enrolment, lower utilisation and payer pushback.
WHO WE WORK WITH
Built for the people
making high-stakes decisions
Investors & BD Teams
Due diligence, in-licensing, partnering
You’re deciding whether to back or license an asset. We give you an independent view of what it takes to make it, what it will cost, and where the plan is exposed.
Biotech & CDMO
Founders, CMC and operations teams
You’re choosing a technology, a route or a scale-up path. We help you test the plan and make the call on solid ground, and give investors and partners a stronger story.
WHO WE ARE

Dr. Setu Kasera, Independent Consultant. Setu is a chemist by training and her background combines R&D finance and technical due diligence for investors, CMC and techno economic assessments, and development of regulatory-grade automated systems for complex processes. She holds a PhD and MPhil in Chemistry from the University of Cambridge, UK and is currently based in Germany.

Dr. Javier Varela, PhD, Independent Associate Consultant. Javier is a microbiologist and metabolic engineer with more than ten years hands-on experience in biotechnology, including pilot-scale fermentation and industrial strain engineering. He holds a PhD in Microbiology from University of Cork, Ireland and MSc Biochemistry from Universidad de Santiago de Chile, and is currently based in Chile.
TALK TO US
Schedule an initial review.
Weighing an automation decision, or reviewing one in a deal?
We will take an initial look at where your manufacturing plan (or its automation case) is strongest and weakest, and if it’s useful, we can go deeper in a written review.
We will not share your details with any third parties.
